Launched in early 2012, this initiative includes 20 hospitals and three radiation oncology facilities across the state working in collaboration with Blue Cross Blue Shield of Michigan and Blue Care Network to determine most appropriate use of intensity modulated radiation therapy for breast and lung cancer patients.
Intensity modulated radiation therapy, or IMRT, is a complex and costly technology that delivers radiation directly to the affected cancerous site, with minimal damage to surrounding healthy tissues. However, it can result in acute levels of toxicity for cancer patients.
In this first-of-its-kind initiative, physicians are creating a data registry of lung and breast cancer patients. Registry data will include reports from the patients themselves, along with clinical data on treatments and outcomes.
For more information, go to mroqc.org.
As MROQC gathers data to achieve the goal of identifying those patients best treated with IMRT, they have improved the quality of radiation therapy throughout the state.
Quality improvement initiative results include:
- An increase in the use of accelerated whole breast irradiation in eligible patients from 36 percent to 85 percent since 2014, with a goal of 85 percent consortium-wide.
- An increase in the use of motion assessment in lung cancer patients from 53 percent to 86 percent since 2014, with a goal of 90 percent consortium-wide.